NOVN.CH

119.52

+0.02%↑

NOVN.CH

119.52

+0.02%↑

NOVN.CH

119.52

+0.02%↑

NOVN.CH

119.52

+0.02%↑

NOVN.CH

119.52

+0.02%↑

Home・Akcijų sąrašas・Lonza Group AG
Search

Lonza Group AG

Atidarymo kaina

SektoriusSveikatos priežiūra

494.8 0.22

Stiprus pirkimas

Kainos atnaujinimas 2026-05-26 08:05; UTC

PirktiParduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

493.4

Max

497.4

Pagrindiniai rodikliai

By Trading Economics

Pajamos

57M

483M

Pardavimai

-621M

3B

P/E

Sektoriaus vid.

35.968

49.701

Dividendų pajamingumas

1.07

Pelno marža

16.345

Darbuotojai

20,000

EBITDA

-181M

822M

Rekomendacijos

By TipRanks

Rekomendacijos

Stiprus pirkimas

12 mėnesių prognozė

+37.24% upside

Dividendai

By Dow Jones

Dividendų pajamingumas

Sektoriaus vid.

1.07%

2.39%

Kitas uždarbis

2026-07-22

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

-6B

33B

Ankstesnė atidarymo kaina

494.58

Ankstesnė uždarymo kaina

494.8

Naujienos nuotaikos

By Acuity

14%

86%

17 / 345 reitingas Healthcare

Lonza Group AG Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-03-06 17:44; UTC

Įsigijimai, susijungimai, perėmimai

Lonza to Offload Majority Stake in Capsule Business to Lone Star in $2.2 Billion Deal

DJ

Skaityti

2026-01-28 06:15; UTC

Uždarbis

Lonza Sales Grow on New Contract Momentum

DJ

Skaityti

2025-07-23 08:30; UTC

Uždarbis
Pagrindinės rinkos jėgos

Lonza Shares Rise After Outlook Lift for Core Business

DJ

Skaityti

2026-05-15 10:45; UTC

Rinkos pokalbiai

Contract Drug Manufacturers to Benefit From U.S. Pharma Onshoring Push -- Market Talk

DJ

Skaityti

2026-05-08 13:44; UTC

Rinkos pokalbiai
Uždarbis

Lonza Update Should Reassure on Outlook -- Market Talk

DJ

Skaityti

2026-03-09 10:34; UTC

Rinkos pokalbiai

Lonza Might Disappoint Investors With Capsule Business Valuation -- Market Talk

DJ

Skaityti

2026-03-06 17:12; UTC

Įsigijimai, susijungimai, perėmimai

Correct: Lonza to Sell Capsules & Health Ingredients Business to Lone Star Funds

DJ

Skaityti

2026-03-06 17:10; UTC

Įsigijimai, susijungimai, perėmimai

Lonza: Total Undiscounted Proceeds Expected to Be at or Above CHF3B

DJ

Skaityti

2026-03-06 17:09; UTC

Įsigijimai, susijungimai, perėmimai

Lonza to Retain 40% Stake in CHI

DJ

Skaityti

2026-03-06 17:08; UTC

Įsigijimai, susijungimai, perėmimai

Lonza Will Receive Upfront Proceeds of CHF1.7B

DJ

Skaityti

2026-03-06 17:07; UTC

Įsigijimai, susijungimai, perėmimai

Lonza: Transaction Expected to Close in 2H

DJ

Skaityti

2026-03-06 17:07; UTC

Įsigijimai, susijungimai, perėmimai

Lonza: This Is for Enterprise Value of CHF2.3B at Closing

DJ

Skaityti

2026-03-06 17:06; UTC

Įsigijimai, susijungimai, perėmimai

Lonza to Sell Capsules & Health Ingredients Business Lone Star Funds

DJ

Skaityti

2026-01-28 12:04; UTC

Rinkos pokalbiai
Uždarbis

Lonza Results Show a Company in Good Shape -- Market Talk

DJ

Skaityti

2026-01-28 05:35; UTC

Uždarbis

Lonza Anticipates 2026 Core EBITDA Margin to Reach Level Above 32%

DJ

Skaityti

2026-01-28 05:34; UTC

Uždarbis

Lonza Anticipates 2026 Sales Growth of 11-12% at CER

DJ

Skaityti

2026-01-28 05:33; UTC

Uždarbis

Lonza Issues 2026 View

DJ

Skaityti

2026-01-28 05:32; UTC

Uždarbis

Lonza 2025 Core Ebitda Margin 31.6%

DJ

Skaityti

2026-01-28 05:32; UTC

Uždarbis

Analysts Saw Lonza 2025 Core Ebitda at CHF2.27B

DJ

Skaityti

2026-01-28 05:32; UTC

Uždarbis

Lonza 2025 Core Ebitda CHF2.06B

DJ

Skaityti

2026-01-28 05:30; UTC

Uždarbis

Analysts Saw Lonza 2025 Sales at CHF7.54B

DJ

Skaityti

2026-01-28 05:30; UTC

Uždarbis

Lonza 2025 Sales CHF6.53B

DJ

Skaityti

2025-10-27 08:24; UTC

Rinkos pokalbiai

Lonza on Track to Meet Long-Term Goals -- Market Talk

DJ

Skaityti

2025-10-23 10:53; UTC

Rinkos pokalbiai
Uždarbis

Lonza Set to Recover as Contracts Flow in -- Market Talk

DJ

Skaityti

2025-07-23 08:00; UTC

Rinkos pokalbiai
Uždarbis

Lonza Nudges Up Full-Year Guidance for Core Business After Good Results -- Market Talk

DJ

Skaityti

2025-07-23 04:44; UTC

Uždarbis

Lonza 1H Sales Grew 19% at Constant Currency

DJ

Skaityti

2025-07-23 04:43; UTC

Uždarbis

Lonza 1H Core Ebitda Margin 29.6%

DJ

Skaityti

2025-07-23 04:43; UTC

Uždarbis

Lonza: Margins Will Be Only Minimally Affected

DJ

Skaityti

2025-07-23 04:42; UTC

Uždarbis

Lonza Expects FX Headwind of -2.5% to -3.5% on 2025 Sales and Core Ebitda

DJ

Skaityti

2025-07-23 04:42; UTC

Uždarbis

Lonza: This Is Mainly From Weakening of U.S. Dollar

DJ

Skaityti

Akcijų palyginimas

Kainos pokytis

Lonza Group AG Prognozė

Kainos tikslas

By TipRanks

37.24% į viršų

12 mėnesių prognozė

Vidutinis 676.33 CHF  37.24%

Aukščiausias 762 CHF

Žemiausias 630 CHF

Remiantis 6 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Lonza Group AG kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

6 ratings

6

Pirkti

0

Laikyti

0

Parduoti

Remiantis 6 analitikų, pateikusių Lonza Group AG akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Rinkos nuotaikos

By Acuity

17 / 345 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Labai stiprus bulių rinkos įrodymas

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Žemiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Lonza Group AG

Lonza Group AG, together with its subsidiaries, supplies various products and services for pharmaceutical, biotech, and nutrition markets in Europe, North and Central America, Latin America, Asia, Australia, New Zealand, and internationally. It operates through Biologics, Small Molecules, Cell & Gene, and Capsules & Health Ingredients segments. The Biologics segment engages in the contract development and manufacturing of biopharmaceuticals for clinical and commercial manufacturing needs throughout the product lifecycle, including drug substance and drug product manufacturing. The Small Molecules segment operates as an integrated development and manufacturing service provider for small molecule drug substances and their intermediates. This segment also supports customers across various aspects of design, development, and manufacturing, including particle engineering and drug product packaging. The Cell & Gene segment develops technologies and platforms that industrialize the manufacturing processes and production of cell and gene therapies; offers contract development and manufacturing services, and regulatory support for a range of allogeneic and autologous cell therapies, and exosome-based therapies, as well as viral vector gene therapies. This segment also provides Cocoon platform, a closed automated system for patient-scale cell therapy manufacturing; and specialty raw materials and enabling technology solutions in cell and gene therapy, injectable drugs, vaccines, and bio-manufacturing markets. The Capsules & Health Ingredients segment offers capsules, dosage form solutions, and health ingredients for pharmaceutical and nutraceutical customers. Lonza Group AG was incorporated in 1897 and is headquartered in Basel, Switzerland.

Kitos sektoriaus akcijos

NOVN.CH

Novartis AG

119.52

↑ +0.02%
help-icon Live chat